Intellia Therapeutics, Inc. (NTLA) is a Biotechnology company in the Healthcare sector, currently trading at $14.78. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is NTLA = $19 (+31.1% upside).
Valuation: NTLA trades at a trailing Price-to-Earnings (P/E) of -3.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Financials: revenue is $68M, +15.4%/yr average growth. Net income is $413M (loss), growing at +4.8%/yr. Net profit margin is -609.9% (negative). Gross margin is 76.5% (-9 pp trend).
Balance sheet: total debt is $93M against $671M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 5.08 (strong liquidity). Debt-to-assets is 11.1%. Total assets: $842M.
Analyst outlook: 28 / 39 analysts rate NTLA as buy (72%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 47/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).
